Ashburton Jersey Ltd lowered its stake in shares of Eli Lilly And Co (NYSE:LLY) by 12.7% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 8,185 shares of the company’s stock after selling 1,190 shares during the period. Ashburton Jersey Ltd’s holdings in Eli Lilly And Co were worth $698,000 as of its most recent SEC filing.
A number of other hedge funds also recently added to or reduced their stakes in LLY. Ironwood Financial llc acquired a new position in Eli Lilly And Co during the 4th quarter valued at about $30,000. Csenge Advisory Group acquired a new position in Eli Lilly And Co during the 3rd quarter valued at about $58,000. Cornerstone Advisors Inc. boosted its stake in Eli Lilly And Co by 21.3% during the 3rd quarter. Cornerstone Advisors Inc. now owns 776 shares of the company’s stock valued at $83,000 after purchasing an additional 136 shares during the last quarter. Atwood & Palmer Inc. boosted its stake in Eli Lilly And Co by 267.0% during the 4th quarter. Atwood & Palmer Inc. now owns 734 shares of the company’s stock valued at $85,000 after purchasing an additional 534 shares during the last quarter. Finally, First Command Bank boosted its stake in Eli Lilly And Co by 31.3% during the 4th quarter. First Command Bank now owns 834 shares of the company’s stock valued at $96,000 after purchasing an additional 199 shares during the last quarter. Institutional investors and hedge funds own 80.84% of the company’s stock.
In related news, major shareholder Lilly Endowment Inc sold 200,000 shares of the company’s stock in a transaction that occurred on Friday, November 16th. The stock was sold at an average price of $113.74, for a total value of $22,748,000.00. Following the transaction, the insider now owns 118,600,804 shares in the company, valued at $13,489,655,446.96. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Myles O’neill sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, December 10th. The shares were sold at an average price of $112.92, for a total value of $2,823,000.00. Following the completion of the transaction, the senior vice president now owns 26,562 shares in the company, valued at approximately $2,999,381.04. The disclosure for this sale can be found here. In the last quarter, insiders sold 817,843 shares of company stock worth $94,595,335. 0.11% of the stock is owned by company insiders.
Eli Lilly And Co (NYSE:LLY) last announced its earnings results on Wednesday, February 6th. The company reported $1.33 earnings per share for the quarter, missing analysts’ consensus estimates of $1.36 by ($0.03). Eli Lilly And Co had a return on equity of 42.55% and a net margin of 13.16%. The business had revenue of $6.44 billion during the quarter, compared to analysts’ expectations of $6.28 billion. During the same quarter in the previous year, the firm earned $1.14 EPS. Eli Lilly And Co’s quarterly revenue was up 4.5% on a year-over-year basis. On average, analysts forecast that Eli Lilly And Co will post 5.6 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 8th. Investors of record on Friday, February 15th will be paid a $0.645 dividend. This is an increase from Eli Lilly And Co’s previous quarterly dividend of $0.56. The ex-dividend date of this dividend is Thursday, February 14th. This represents a $2.58 annualized dividend and a yield of 2.16%. Eli Lilly And Co’s dividend payout ratio is presently 40.54%.
A number of research firms have issued reports on LLY. Cantor Fitzgerald reiterated a “buy” rating and set a $128.00 price target on shares of Eli Lilly And Co in a research note on Wednesday, October 17th. Credit Suisse Group upgraded Eli Lilly And Co from an “underperform” rating to a “neutral” rating in a research note on Wednesday, October 31st. Citigroup downgraded Eli Lilly And Co from a “buy” rating to a “neutral” rating and set a $115.00 price target for the company. in a research note on Monday, November 26th. ValuEngine downgraded Eli Lilly And Co from a “buy” rating to a “hold” rating in a research note on Tuesday, November 6th. Finally, Zacks Investment Research upgraded Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $121.00 target price on the stock in a research note on Wednesday, December 19th. Eleven research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $111.41.
COPYRIGHT VIOLATION NOTICE: “Ashburton Jersey Ltd Has $698,000 Holdings in Eli Lilly And Co (LLY)” was first posted by Ticker Report and is owned by of Ticker Report. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://www.tickerreport.com/banking-finance/4147606/ashburton-jersey-ltd-has-698000-holdings-in-eli-lilly-and-co-lly.html.
Eli Lilly And Co Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
See Also: Cash Flow
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.